Alzheimer’s trial updates in Q1 2026 drove biotech stock moves as investors assessed clinical data, safety, and approval potential.
Healthcare Stocks
May 12, 2026
Table of Contents
May 11, 2026
Several biotech companies reported Alzheimer’s disease and adjacent neurodegenerative trial updates in 2026, drawing investor attention as markets reacted to clinical data, safety findings, biomarker signals, and changes in treatment outlook.
Alzheimer’s trial results can move stocks sharply because the disease represents one of the largest unmet needs in healthcare. Positive data can increase the perceived probability of approval, partnership interest, and future revenue potential. Negative or mixed updates can erase value quickly, especially for smaller biotech firms that rely heavily on one lead program.
This list includes Alzheimer’s-focused updates and related neurodegenerative programs with Alzheimer’s relevance, including Alzamend Neuro, Ovid Therapeutics, Alector, CervoMed, Denali Therapeutics, Coya Therapeutics, and Neumora Therapeutics.
Alzheimer’s clinical trial updates are high-impact biotech catalysts because they can change the market’s view of a drug’s probability of success.
Investors typically react to:
The stock reaction is usually strongest when the Alzheimer’s program represents a major part of the company’s pipeline or future valuation.
Price: $1.05
Date: March 26, 2026
1-day impact: -22.28%
Alzamend Neuro reported pharmacodynamic data from its Phase 2 clinical trial of AL001, also referred to as the “Lithium in Brain” study, conducted at Massachusetts General Hospital.
Alzamend Neuro is a clinical-stage biotechnology company developing treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.
The stock fell 22.28% after the update, making it the largest Alzheimer’s-related move in the group. The reaction suggests investors may have viewed the data as insufficient to remove uncertainty around AL001’s clinical path, even if the company described the results as encouraging.
Key details:
Drug candidate: AL001
Trial phase: Phase 2
Patient population: Alzheimer’s-related lithium brain exposure study
Primary endpoint: Pharmacodynamic / lithium exposure data
Result: Encouraging pharmacodynamic data, according to the company
Safety signal: Not specified in provided data
Announcement date: March 26, 2026
1-day stock move: -22.28%
Next expected milestone: Additional clinical development updates
Price: $2.79
Date: March 18, 2026
1-day impact: +14.43%
Ovid Therapeutics moved after updates tied to OV4071, which the company said may have therapeutic potential across neuropsychiatric disorders characterized by neural circuit dysfunction, including schizophrenia and psychosis associated with Alzheimer’s disease.
Ovid Therapeutics is a biopharmaceutical company developing medicines for neurological and neuropsychiatric disorders.
Shares rose 14.43%, suggesting investors responded favorably to the broader potential of OV4071 beyond a single indication. The Alzheimer’s relevance here is not traditional Alzheimer’s cognitive decline, but psychosis associated with Alzheimer’s disease.
Key details:
Drug candidate: OV4071
Trial phase: Not specified in provided data
Patient population: Neuropsychiatric disorders, including psychosis associated with Alzheimer’s disease
Primary endpoint: Not specified
Result: Broader therapeutic potential highlighted
Safety signal: Not specified
Announcement date: March 18, 2026
1-day stock move: +14.43%
Next expected milestone: Further clinical program updates
Price: $2.05
Date: May 7, 2026
1-day impact: -5.06%
Alector reported continued progress across its Alector Brain Carrier platform, including AL037/AL137, an ABC-enabled antibody program for Alzheimer’s disease, and AL064/AL164, an ABC-enabled Tau siRNA program for Alzheimer’s disease and other tauopathies.
Alector is a biotechnology company focused on neurodegenerative diseases, using immunology, genetics, and brain delivery technologies to develop therapies for Alzheimer’s, Parkinson’s, frontotemporal dementia, and related conditions.
Shares fell 5.06% after the update. The decline suggests investors may have wanted clearer clinical data or more defined near-term milestones rather than broader platform progress.
Key details:
Drug candidate: AL037/AL137 and AL064/AL164
Trial phase: Platform / pipeline progress update
Patient population: Alzheimer’s disease and other tauopathies
Primary endpoint: Not specified
Result: Continued platform progress
Safety signal: Not specified
Announcement date: May 7, 2026
1-day stock move: -5.06%
Next expected milestone: Further clinical and platform updates
Price: $1.05
Date: April 7, 2026
1-day impact: -2.47%
Alzamend Neuro also appeared again in April with another Alzheimer’s-related trial update tied to AL001.
Shares fell 2.47% after this later event, a smaller decline than the March 26 reaction. The repeated negative moves suggest investors remained cautious about the program’s development path and whether the data would translate into a stronger regulatory or commercial case.
Key details:
Drug candidate: AL001
Trial phase: Phase 2
Patient population: Alzheimer’s-related study
Primary endpoint: Pharmacodynamic / lithium exposure data
Result: Encouraging data previously reported, but market reaction remained negative
Safety signal: Not specified
Announcement date: April 7, 2026
1-day stock move: -2.47%
Next expected milestone: Further clinical development updates
Price: $19.67
Date: February 26, 2026
1-day impact: -1.12%
Denali Therapeutics highlighted DNL628, also known as OTV:MAPT, for Alzheimer’s disease.
Denali is a biotechnology company developing therapies for neurodegenerative diseases, using its transport vehicle platform to deliver biologic medicines across the blood-brain barrier.
DNL628 is designed to cross the blood-brain barrier and reduce tau protein by targeting the MAPT gene that encodes tau. Shares fell 1.12%, suggesting investors viewed the update as early-stage or not yet strong enough to change the near-term valuation.
Key details:
Drug candidate: DNL628 / OTV:MAPT
Trial phase: Not specified in provided data
Patient population: Alzheimer’s disease
Primary endpoint: Tau reduction / MAPT targeting
Result: Program update
Safety signal: Not specified
Announcement date: February 26, 2026
1-day stock move: -1.12%
Next expected milestone: Further preclinical or clinical development updates
Price: $4.18
Date: January 8, 2026
1-day impact: -0.58%
Coya Therapeutics announced positive results from an investigator-initiated proof-of-concept open-label study using low-dose IL-2 and CTLA4-Ig combination treatment in nine patients with frontotemporal dementia over six months.
Coya Therapeutics is a clinical-stage biotechnology company developing biologics that enhance regulatory T cell function in patients with neurodegenerative disorders.
This was not an Alzheimer’s disease trial, but it belongs in the broader neurodegenerative disease context because frontotemporal dementia shares relevance with the larger dementia treatment landscape. Shares fell 0.58%, suggesting the market reaction was muted despite the positive study language.
Key details:
Drug candidate: Low-dose IL-2 plus CTLA4-Ig combination
Trial phase: Proof-of-concept open-label study
Patient population: Frontotemporal dementia
Primary endpoint: Not specified in provided data
Result: Positive results reported
Safety signal: Not specified
Announcement date: January 8, 2026
1-day stock move: -0.58%
Next expected milestone: Larger controlled study or further development update
Price: $3.80
Date: March 19, 2026
1-day impact: -0.24%
CervoMed announced new data at the AD/PD 2026 Scientific Conference reinforcing neflamapimod’s positive effects in dementia with Lewy bodies patients without Alzheimer’s disease co-pathology.
CervoMed is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders.
This update is adjacent to Alzheimer’s rather than a direct Alzheimer’s trial result. The focus was dementia with Lewy bodies, specifically patients without Alzheimer’s disease co-pathology. Shares fell 0.24%, showing a muted market reaction.
Key details:
Drug candidate: Neflamapimod
Trial phase: Data update presented at AD/PD 2026
Patient population: Dementia with Lewy bodies patients without Alzheimer’s disease co-pathology
Primary endpoint: Not specified in provided data
Result: Positive effects reinforced
Safety signal: Not specified
Announcement date: March 19, 2026
1-day stock move: -0.24%
Next expected milestone: Further clinical data or development update
Price: $1.87
Date: January 5, 2026
1-day impact: 0.00%
Neumora Therapeutics announced positive results from its NMRA-511 Phase 1b signal-seeking study in Alzheimer’s disease agitation.
Neumora is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases and neuropsychiatric disorders.
The stock reaction was flat, suggesting investors did not view the early-stage signal-seeking study as a major valuation-changing event. Still, Alzheimer’s agitation represents a clinically important area where treatment options remain limited.
Key details:
Drug candidate: NMRA-511
Trial phase: Phase 1b signal-seeking study
Patient population: Alzheimer’s disease agitation
Primary endpoint: Not specified in provided data
Result: Positive results reported
Safety signal: Not specified
Announcement date: January 5, 2026
1-day stock move: 0.00%
Next expected milestone: Additional clinical development update
The largest Alzheimer’s-related trial moves in this group were:
Alzamend Neuro (NASDAQ: ALZN): -22.28%
Ovid Therapeutics (NASDAQ: OVID): +14.43%
Alector (NASDAQ: ALEC): -5.06%
Alzamend Neuro (NASDAQ: ALZN): -2.47%
Denali Therapeutics (NASDAQ: DNLI): -1.12%
The biggest negative reaction came from Alzamend Neuro’s March 26 update. The biggest positive reaction came from Ovid Therapeutics.
Not every Alzheimer’s trial update produces the same stock reaction.
The biggest moves usually occur when:
Alzamend moved sharply because investors reacted to Phase 2 Alzheimer’s-related data from a small-cap biotech. Ovid moved higher because its update suggested broader therapeutic potential across neuropsychiatric disorders, including psychosis associated with Alzheimer’s disease.
Small-cap biotech firms often see the largest price swings after Alzheimer’s data because one program may represent most of the company’s future value.
Positive data can lead to sharp rallies on expectations of higher approval probability, partnership interest, acquisition speculation, financing opportunities, or expanded clinical development.
Negative or unclear data can cause large declines if the company has limited backup pipeline assets.
Alzheimer’s trial results are among the most important biotech events because they can reshape expectations for approval probability, future revenue, and competitive positioning.
The strongest reactions usually occur when data is clinically meaningful, safety is manageable, and the drug is central to the company’s valuation.
Platforms like LevelFields track Alzheimer’s trial results and other biotech catalysts in real time, helping investors identify when clinical trial events have historically led to meaningful stock moves.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE